About Merck
Merck is a company based in Cambridge (United States) founded in 2015 was acquired by Merck Sharp & Dohme in January 2024. It operates as a Direct-to-Consumer (D2C) and Professional Services. Merck has raised $130 million across 5 funding rounds from investors including UBS, New Leaf Venture Partners and Citadel. The company has 93 employees as of December 31, 2021. Merck offers products and services including Medicines and Vaccines and Animal Health Products. Merck operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 93 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Merck & Co., Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$130 M (USD)
in 5 rounds
-
Latest Funding Round
$100.16 M (USD), Post-IPO
Oct 23, 2023
-
Investors
UBS
& 19 more
-
Employee Count
93
as on Dec 31, 2021
-
Acquired by
Merck Sharp & Dohme
(Jan 08, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Merck
Merck offers a comprehensive portfolio of products and services, including Medicines and Vaccines and Animal Health Products.
Medicines and vaccines are developed for various diseases.
Products for animal health are offered globally.
People of Merck
Unlock access to complete
Funding Insights of Merck
Merck has successfully raised a total of $130M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100.16 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Merck
Merck has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include UBS, New Leaf Venture Partners and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital is provided to healthcare startups by Commodore Capital.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked |
Investor details for Merck
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Merck
Investment portfolio details for Merck
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Merck
Detailed financials for Merck
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Merck Comparisons
Peer comparison for Merck
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Merck
Merck operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Merck
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Merck
Complete news archive for Merck
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merck
Merck was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Merck is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Merck is a funded company, having raised a total of $130M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Merck is 93.
Merck is established as a premier biopharmaceutical company focused on research and development. The company is engaged in creating innovative medicines and vaccines across various therapeutic areas including oncology, infectious diseases, and cardio-metabolic disorders. Solutions are developed through advanced data science, artificial intelligence, and sustainable science practices. Operations are conducted with a commitment to sustainability, aiming to benefit global communities. The companys efforts are directed towards addressing critical health challenges and improving patient outcomes worldwide.
Merck's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Merck offers Medicines and Vaccines and Animal Health Products.
Merck has 20 investors. Key investors include UBS, New Leaf Venture Partners, Citadel, Orbimed, and RA Capital.